Company news

Aquestive Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Aquestive Therapeutics to Report Third Quarter 2026 Financial Results and Recent Business Highlights on November 3 and Host Conference Call on November 4 at 8: 00 a.m. ET

October 27, 2026

Aquestive Therapeutics Announces FDA Acceptance of Anaphylm™ NDA Resubmission and PDUFA Goal Date of March 16, 2027

October 15, 2026

Eton Pharmaceuticals and Aquestive Therapeutics Announce Exclusive U.S. Licensing Agreement for LIBERVANT® (diazepam) Buccal Film

October 14, 2026

Aquestive Therapeutics Strengthens Board of Directors with Appointment of Richard Daly

September 29, 2026

Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

September 17, 2026

Aquestive Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

August 11, 2026

Aquestive Therapeutics Announces Positive Topline Human Factors and Pharmacokinetic Study Results for Anaphylm™ (dibutepinephrine) Sublingual Film

August 10, 2026

Aquestive Therapeutics to Report Second Quarter 2026 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8: 00 a.m. ET

July 29, 2026

Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

May 13, 2026

Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree

May 12, 2026

Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8: 00 a.m. ET

May 6, 2026

Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film

March 29, 2026

Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer

March 20, 2026

Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)

March 8, 2026

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

March 3, 2026

Aquestive Therapeutics to Participate in Upcoming March Investor Conferences

February 25, 2026

Aquestive Therapeutics to Report Fourth Quarter 2025 Financial Results and Recent Business Highlights on March 4 and Host Conference Call on March 5 at 8: 00 a.m. ET

February 24, 2026

Aquestive Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 23, 2026

Aquestive Therapeutics to Present New Clinical Data on Anaphylm™ (dibutepinephrine) Sublingual Film at the 2026 AAAAI Annual Meeting

February 19, 2026

Aquestive Therapeutics Appoints Internationally Recognized Allergist Dr. Matthew Greenhawt as Chief Medical Officer

February 17, 2026

Aquestive Therapeutics Announces FDA Issuance of Complete Response Letter for Anaphylm™

February 1, 2026

Aquestive Therapeutics Announces Regulatory Development for Anaphylm™ (dibutepinephrine) Sublingual Film and Provides Business Update

January 8, 2026

Aquestive Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference

November 23, 2025

Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

November 4, 2025

Aquestive Therapeutics Announces Leadership Expansion to Support Growth

November 3, 2025

Aquestive Therapeutics to Participate in a Fireside Chat Hosted by Piper Sandler

November 2, 2025

Aquestive Therapeutics to Attend 2025 ACAAI Annual Meeting

October 29, 2025

Aquestive Therapeutics to Report Third Quarter 2025 Financial Results and Recent Business Highlights on November 5 and Host Conference Call on November 6 at 8: 00 a.m. ET

October 26, 2025

Aquestive Therapeutics Broadens Patent Estate for Anaphylm™

October 7, 2025

Aquestive Therapeutics Announces that FDA Will Not Require an Advisory Committee Meeting to Discuss New Drug Application for Anaphylm™

September 3, 2025

Aquestive Therapeutics to Participate in Upcoming September Investor Conferences

August 25, 2025

Aquestive Therapeutics Announces Pricing of $85 Million Underwritten Offering of Common Stock

August 13, 2025

Aquestive Therapeutics Announces $75M Strategic Funding Agreement with RTW to Support the Potential Launch of Anaphylm™ (epinephrine) Sublingual Film

August 13, 2025

Aquestive Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

August 10, 2025

Aquestive Therapeutics to Report Second Quarter 2025 Financial Results and Recent Business Highlights on August 11 and Host Conference Call on August 12 at 8: 00 a.m. ET

August 3, 2025

Aquestive Therapeutics Names Sherry Korczynski as Chief Commercial Officer

July 21, 2025

Aquestive Therapeutics Provides International Expansion Update for Anaphylm™ (epinephrine) Sublingual Film

July 14, 2025

Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm™ (epinephrine) Sublingual Film at the CFAAR Food Allergy Summit

June 24, 2025

Aquestive Therapeutics Announces FDA Acceptance of New Drug Application and PDUFA Date for Anaphylm™ for the Treatment of Severe Allergic Reactions

June 15, 2025

Aquestive Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 11, 2025

Aquestive Therapeutics to Participate in Citizens Life Sciences Conference

May 4, 2025

Aquestive Therapeutics to Report First Quarter 2025 Financial Results and Recent Business Highlights on May 12 and Host Conference Call on May 13 at 8: 00 a.m. ET

April 30, 2025

Aquestive Therapeutics to Participate in Piper Sandler Spring Biopharma Symposium

April 8, 2025

Aquestive Therapeutics Announces Positive Topline PK Results from its Pediatric Study and Completes the NDA Submission for Anaphylm™ (epinephrine) Sublingual Film

March 31, 2025

Aquestive Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

March 4, 2025

Aquestive Therapeutics to Participate in Two Upcoming Conferences in March

February 25, 2025

Aquestive Therapeutics to Report Fourth Quarter 2024 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8: 00 a.m. ET

February 19, 2025

Aquestive Therapeutics to Present New Findings on Anaphylm™ (Epinephrine Sublingual Film) at the 2025 AAAAI Annual Meeting

February 11, 2025

Aquestive Therapeutics to Participate in Oppenheimer 35th Annual Healthcare Conference

February 3, 2025

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

January 12, 2025

Older news releases →

Calls

The 5 newest of 22 calls. Every call is listed under its year.

Decks

The 5 newest of 58 decks. Every deck is listed under its year.